Fig. 1
From: PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model
High expression of PHF6 in AML patients with MLL rearrangement. (A) Comparison of PHF6 expression in AML patients with MLL rearrangement (11q23/MLL) and in healthy myeloid cells (Data from bloodspot dataset, www.bloodspot.eu); (B) Comparison of PHF6 expression in AML cases with MLL rearrangements (11q23/MLL) and without MLL rearrangements (non-MLL). Inv [16], t (8;21) and t (15;17) are AML subtypes (Published microarray dataset [26]); (C-D) PHF6 was highly expressed in AML patients with MLL rearrangements (Data from oncomine dataset, https://www.oncomine.org); (E) Survival analysis of AML patients (Data from gepia dataset, http://gepia.cancer-pku.cn/detail.php?gene=PHF6). 106 AML patients were ranked from high to low based on PHF6 expression, and the median was determined. The 53 AML patients above the median of PHF6 expression were classified as high expression group; The 53 AML patients below the median of PHF6 expression were classified as low expression group. Log-rank (Mantel–Cox) test was used. A two-sided P < 0.05 was considered statistically significant